- Home
- XNCR vs KROS Comparison
XNCR vs KROS Comparison
Compare XNCR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- KROS
- Stock Information
- Founded
- XNCR 1997
- KROS 2015
- Country
- XNCR United States
- KROS United States
- Employees
- XNCR N/A
- KROS N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- XNCR Health Care
- KROS Health Care
- Exchange
- XNCR Nasdaq
- KROS Nasdaq
- Market Cap
- XNCR 547.8M
- KROS 565.0M
- IPO Year
- XNCR 2013
- KROS 2020
- Fundamental
- Price
- XNCR $8.48
- KROS $15.54
- Analyst Decision
- XNCR Buy
- KROS Buy
- Analyst Count
- XNCR 10
- KROS 14
- Target Price
- XNCR $23.33
- KROS $20.56
- AVG Volume (30 Days)
- XNCR 734.4K
- KROS 430.7K
- Earning Date
- XNCR 11-05-2025
- KROS 11-05-2025
- Dividend Yield
- XNCR N/A
- KROS N/A
- EPS Growth
- XNCR N/A
- KROS N/A
- EPS
- XNCR N/A
- KROS 0.47
- Revenue
- XNCR $146,929,000.00
- KROS $232,844,000.00
- Revenue This Year
- XNCR $22.06
- KROS $5,579.44
- Revenue Next Year
- XNCR N/A
- KROS N/A
- P/E Ratio
- XNCR N/A
- KROS $33.65
- Revenue Growth
- XNCR N/A
- KROS 85820.30
- 52 Week Low
- XNCR $6.92
- KROS $9.12
- 52 Week High
- XNCR $27.24
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- XNCR 55.05
- KROS 56.89
- Support Level
- XNCR $8.26
- KROS $15.23
- Resistance Level
- XNCR $8.73
- KROS $15.85
- Average True Range (ATR)
- XNCR 0.38
- KROS 0.48
- MACD
- XNCR 0.06
- KROS -0.01
- Stochastic Oscillator
- XNCR 68.14
- KROS 64.21
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.